Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice
Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease caused by an absence of the dystrophin protein, which is essential for muscle fiber integrity. Among the developed therapeutic strategies for DMD, exon skipping approach corrects the frame shift and partially restores dystrophi...
Main Authors: | Forand, A, Muchir, A, Mougenot, N, Sevoz-Couche, C, Peccate, C, Le Maitre, M, Izabelle, C, Wood, MJA, Lorain, S, Piétri-Rouxel, F |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2020
|
Similar Items
-
Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
by: Li, Chengxi, et al.
Published: (2021) -
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study
by: Cirak, S, et al.
Published: (2011) -
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
by: Cirak, S, et al.
Published: (2011) -
AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
by: Le Hir, M, et al.
Published: (2013) -
PPMO's as therapeutic modulators for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)